Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00699816|
Recruitment Status : Completed
First Posted : June 18, 2008
Results First Posted : September 24, 2015
Last Update Posted : October 26, 2017
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Hepatocellular Carcinoma||Biological: Immuncell-LC||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||230 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'Green Cross CELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection(PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea|
|Study Start Date :||July 2008|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||November 2012|
Experimental: Immunotherapy Group
Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
Activated T lymphocyte
No Intervention: Control Group
Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
- Recurrence Free Survival(RFS) [ Time Frame: Every 3months from the baseline for 24 months and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit) ]RFS was measured from the date of randomization to the first recurrence or to death from any cause.
- Recurrence Free Survival(RFS) Rate [ Time Frame: Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit) ]RFS rate was measured from the date of randomization to the first recurrence or to death from any cause.
- Overall Survival(OS) [ Time Frame: Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit) ]Overall survival was measured from the date of randomization until death from any cause.
- Cancer-specific Survivals [ Time Frame: Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit) ]Cancer-specific survival was measured from the date of randomization until death resulting from HCC.
- Overall Survival(OS) Rate [ Time Frame: Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit) ]Overall survival rate was measured from the date of randomization until death from any cause.
- Cancer-specific Survival Rate [ Time Frame: Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit) ]Cancer-specific survival rate was measured from the date of randomization until death resulting from HCC.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||20 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.
- The patient is more than 20 and less than 80 years old
- The patient is diagnosed as hepatocellular carcinoma by pathological/ radiological test and he (she) is in the stage of I or II. (refer to the attached file 10). Hepatocellular carcinoma should be shown by radiological test; on dynamic CT, dynamic MRI or on angiography.
- Child-Pugh Score should be less than 6 (refer to the attached file 7)
- No matter how the patient has been treated before, his (her) tumor should be totally removed by curative resection (PEIT, RFA or operation) in 12 weeks. (based on the agreement date for written consent) The tumor's removal should be perfectly confirmed by pathological or radiological test with the mentioned method in 3) at least 4 weeks later.
- ECOG Performance status (ECOG-PS) is less than 1 or equal to (refer to the exhibit 8)
- Patient's remaining life-time should be expected at least more than 3 months.
Patient should meet below conditions by blood test, kidney and liver function test
: Re-evaluation is possible during screening
- Leukocyte count is bigger than (3 multiply 109/L)
- Absolute Neutrophil Count (ANC) is bigger than or equal to 1,000/µL
- Hemoglobin is bigger than or equal to 8.5 g/dL
- Thrombocyte count is bigger than (5 multiply 1010/L)
- BUN and serum Creatinine is less than or equal to 1.5 multiply normal upper-limit
- No more disease abdominal extrahepatic transfer is confirmed by abdominal CT/ MRI
- Hepatocellular carcinoma has been transferred by pathological/ radiological test (Stage III or Stage IV, refer to the exhibit 10)
- The carcinoma has been invaded to main portal vein or major branch hepatic vein
- Child-Pugh score is over 6
- Patient has serious problem with pulmonary function by sub- investigator's opinion
- Patient who has disease history of immune deficiency (which can be worse by immunotherapy) or auto-immune disease (ex. arthritis rheumatism, Burger's disease, multiple sclerosis and adolescent-occurred insulin dependent diabetes)
- Diagnosed as an immune deficiency patient
- Patient who has disease history of malignant tumor within 5 years before this clinical trial. (except for skin cancer, local prostate cancer or carcinoma in situ of the uterine cervix
- Patient who had anti-cancer medication before the clinical trial
- Patient who has serious disease in other organs after tumor resection.
- Patient has serious allergic-history by sub- investigator's opinion
- Patient has serious mental disease by sub- investigator's opinion
- Pregnant women, nursing mother or having intention of being pregnant during the clinical test
- Patient who participated in other clinical trial within 4 weeks before this clinical trial
- Patient who is incongruent to this clinical trial by sub- investigator's opinion.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00699816
|Korea, Republic of|
|Korea University Guro Hospital|
|Seoul, Guro 2-Dong, Guro-Gu, Korea, Republic of, 152-703|
|Samsung Medical Center|
|Seoul, Ilwon-dong/Gangnam-gu, Korea, Republic of, 135-710|
|Korea University Ansan Hospital|
|Gojan1-dong, Danwon-gu, Ansan-si, Kyoungi-do, Seoul, Seoul, Korea, Republic of, 425-707|
|Seoul Asan Medical center|
|Pungnab2-dong, Songpa-gu, Seoul, Seoul, Korea, Republic of, 138-736|
|Seoul National University Hospital|
|Seoul, Yeongun-dong/Jongro-gu, Korea, Republic of, 110-744|
|Principal Investigator:||Jung Hwan Yoon, MD||Seoul National University Hospital|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||GC Cell Corporation|
|Other Study ID Numbers:||
|First Posted:||June 18, 2008 Key Record Dates|
|Results First Posted:||September 24, 2015|
|Last Update Posted:||October 26, 2017|
|Last Verified:||August 2015|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases